Limits...
Effect of GCSB-5, a Herbal Formulation, on Monosodium Iodoacetate-Induced Osteoarthritis in Rats.

Kim JK, Park SW, Kang JW, Kim YJ, Lee SY, Shin J, Lee S, Lee SM - Evid Based Complement Alternat Med (2012)

Bottom Line: In vitro, GCSB-5 inhibited proteoglycan degradation.Matrix metalloproteinase (MMP) activity, as well as, the levels of serum tumor necrosis factor-α, cyclooxygenase-2, inducible nitric oxide synthase protein, and mRNA expressions were attenuated by GCSB-5, whereas the level of interleukin-10 was potentiated.By GCSB-5, the level of nuclear factor-κB p65 protein expression was significantly attenuated but, on the other hand, the level of inhibitor of κB-α protein expression was increased.

View Article: PubMed Central - PubMed

Affiliation: School of Pharmacy, Sungkyunkwan University, Suwon, Gyeonggi-do 440-746, Republic of Korea.

ABSTRACT
Therapeutic effects of GCSB-5 on osteoarthritis were measured by the amount of glycosaminoglycan in rabbit articular cartilage explants in vitro, in experimental osteoarthritis induced by intra-articular injection of monoiodoacetate in rats in vivo. GCSB-5 was orally administered for 28 days. In vitro, GCSB-5 inhibited proteoglycan degradation. GCSB-5 significantly suppressed the histological changes in monoiodoacetate-induced osteoarthritis. Matrix metalloproteinase (MMP) activity, as well as, the levels of serum tumor necrosis factor-α, cyclooxygenase-2, inducible nitric oxide synthase protein, and mRNA expressions were attenuated by GCSB-5, whereas the level of interleukin-10 was potentiated. By GCSB-5, the level of nuclear factor-κB p65 protein expression was significantly attenuated but, on the other hand, the level of inhibitor of κB-α protein expression was increased. These results indicate that GCSB-5 is a potential therapeutic agent for the protection of articular cartilage against progression of osteoarthritis through inhibition of MMPs activity, inflammatory mediators, and NF-κB activation.

No MeSH data available.


Related in: MedlinePlus

Activities of MMP-2 (Gelatinase A) and MMP-9 (Gelatinase B) assessed by zymography in knee joint cartilages obtained 28 days after MIA injection. The latent and active amounts of gelatinase were combined to give a total value for each gelatinase. Each value represents the mean ± S.E.M. from 6 rats per group. aSignificantly different (P < 0.01) from control. bSignificantly different (P < 0.05) from vehicle-treated MIA.
© Copyright Policy - open-access
Related In: Results  -  Collection


getmorefigures.php?uid=PMC3303749&req=5

fig3: Activities of MMP-2 (Gelatinase A) and MMP-9 (Gelatinase B) assessed by zymography in knee joint cartilages obtained 28 days after MIA injection. The latent and active amounts of gelatinase were combined to give a total value for each gelatinase. Each value represents the mean ± S.E.M. from 6 rats per group. aSignificantly different (P < 0.01) from control. bSignificantly different (P < 0.05) from vehicle-treated MIA.

Mentions: Seven days after MIA injection, the activities of matrix metalloproteinase (MMP)-2 and -9 increased to 2.7 and 2.4 times that in the control group, respectively. Similarly, 28 days after MIA injection, the activities of MMP-2 and -9 increased to 2.3- and 2.8-fold higher than the control level, respectively. On day 7, GCSB-5 and diclofenac treatment showed no significant modulation on MMP activities (data not shown). However, on day 28, GCSB-5 300 mg/kg treatment exhibited significant MMP-2 and -9 activities attenuation (79.6%, P < 0.01 and 81.2%, P < 0.01, resp.), while GCSB-5 600 mg/kg treatment did not affect the MMP-2 and -9 activities (91.0% and 91.6%, resp.) (Figure 3).


Effect of GCSB-5, a Herbal Formulation, on Monosodium Iodoacetate-Induced Osteoarthritis in Rats.

Kim JK, Park SW, Kang JW, Kim YJ, Lee SY, Shin J, Lee S, Lee SM - Evid Based Complement Alternat Med (2012)

Activities of MMP-2 (Gelatinase A) and MMP-9 (Gelatinase B) assessed by zymography in knee joint cartilages obtained 28 days after MIA injection. The latent and active amounts of gelatinase were combined to give a total value for each gelatinase. Each value represents the mean ± S.E.M. from 6 rats per group. aSignificantly different (P < 0.01) from control. bSignificantly different (P < 0.05) from vehicle-treated MIA.
© Copyright Policy - open-access
Related In: Results  -  Collection

Show All Figures
getmorefigures.php?uid=PMC3303749&req=5

fig3: Activities of MMP-2 (Gelatinase A) and MMP-9 (Gelatinase B) assessed by zymography in knee joint cartilages obtained 28 days after MIA injection. The latent and active amounts of gelatinase were combined to give a total value for each gelatinase. Each value represents the mean ± S.E.M. from 6 rats per group. aSignificantly different (P < 0.01) from control. bSignificantly different (P < 0.05) from vehicle-treated MIA.
Mentions: Seven days after MIA injection, the activities of matrix metalloproteinase (MMP)-2 and -9 increased to 2.7 and 2.4 times that in the control group, respectively. Similarly, 28 days after MIA injection, the activities of MMP-2 and -9 increased to 2.3- and 2.8-fold higher than the control level, respectively. On day 7, GCSB-5 and diclofenac treatment showed no significant modulation on MMP activities (data not shown). However, on day 28, GCSB-5 300 mg/kg treatment exhibited significant MMP-2 and -9 activities attenuation (79.6%, P < 0.01 and 81.2%, P < 0.01, resp.), while GCSB-5 600 mg/kg treatment did not affect the MMP-2 and -9 activities (91.0% and 91.6%, resp.) (Figure 3).

Bottom Line: In vitro, GCSB-5 inhibited proteoglycan degradation.Matrix metalloproteinase (MMP) activity, as well as, the levels of serum tumor necrosis factor-α, cyclooxygenase-2, inducible nitric oxide synthase protein, and mRNA expressions were attenuated by GCSB-5, whereas the level of interleukin-10 was potentiated.By GCSB-5, the level of nuclear factor-κB p65 protein expression was significantly attenuated but, on the other hand, the level of inhibitor of κB-α protein expression was increased.

View Article: PubMed Central - PubMed

Affiliation: School of Pharmacy, Sungkyunkwan University, Suwon, Gyeonggi-do 440-746, Republic of Korea.

ABSTRACT
Therapeutic effects of GCSB-5 on osteoarthritis were measured by the amount of glycosaminoglycan in rabbit articular cartilage explants in vitro, in experimental osteoarthritis induced by intra-articular injection of monoiodoacetate in rats in vivo. GCSB-5 was orally administered for 28 days. In vitro, GCSB-5 inhibited proteoglycan degradation. GCSB-5 significantly suppressed the histological changes in monoiodoacetate-induced osteoarthritis. Matrix metalloproteinase (MMP) activity, as well as, the levels of serum tumor necrosis factor-α, cyclooxygenase-2, inducible nitric oxide synthase protein, and mRNA expressions were attenuated by GCSB-5, whereas the level of interleukin-10 was potentiated. By GCSB-5, the level of nuclear factor-κB p65 protein expression was significantly attenuated but, on the other hand, the level of inhibitor of κB-α protein expression was increased. These results indicate that GCSB-5 is a potential therapeutic agent for the protection of articular cartilage against progression of osteoarthritis through inhibition of MMPs activity, inflammatory mediators, and NF-κB activation.

No MeSH data available.


Related in: MedlinePlus